产品扩散的成本真实存在，大多隐形，且落在承担风险收入的产品上。 数字健康公司面临更难的结构问题：结果风险承诺的速度，超过了公司验证自身能否承担的能力——12个月的测量窗口对上11个月的销售周期。任何可信的方案都必须同时掌握风险收入份额和参与率，而这正是多数内部分析止步之处，因为两者分属不同系统。
产品扩散的成本真实存在，大多隐形，且落在承担风险收入的产品上。 数字健康公司面临更难的结构问题：结果风险承诺的速度，超过了公司验证自身能否承担的能力——12个月的测量窗口对上11个月的销售周期。任何可信的方案都必须同时掌握风险收入份额和参与率，而这正是多数内部分析止步之处，因为两者分属不同系统。
产品和服务线不断累积，因为每一条新增都能用新客户或渠道准入单独证明合理性，从未被移除。成本不在其中任何一条，而在于它们共同造成的复杂性——更多病种的结果追踪、参与率管理、归因结果支持、PMPM预测，以及客户流失压力。
这些成本主要由盈利的核心业务承担，因为那里才有能力承担结果风险。这就是为什么精简往往能提升总利润，即使被移除的条线名义上仍有贡献。
值得做的分析是，按每单位约束贡献度对条线排序——约束即12个月的测量窗口——然后判断尾部哪些有理由存在——战略客户或渠道要求——哪些只是因为没人检查。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 少数产品贡献了大部分稳定的风险收入份额，且客户流失率低
✓ 尽管多次审查产品组合，仍无服务被终止
✓ 已签署的风险合同与已测量的参与率或归因结果之间的差距正在扩大
通常会让情况更糟的做法。 仅按ARR排名砍掉尾部，这会移除那些在结果测量约束上成本低廉的条线，却保留那些悄然消耗11个月销售周期的条线。
It is for you if you run or finance a digital health company and a minority of lines produces the large majority of revenue. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Matrix Strategy, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
先看每单位绑定约束的贡献，再检查战略依赖。仅按收入排名会两头出错。
部分会流失。分析应在决策前而非之后估算损失。通常面临的风险收入小于移除的复杂性成本，但这必须是结论而非假设。
很少被追踪，所以才会增长。一个可行的替代指标是单位业务量的运营成本趋势：当业务量上升而该成本也上升时，复杂性通常是主因。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית